Ibex Investors’s Halozyme HALO Stock Holding History

Ibex Investors’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,739	Closed	-$261K	–	214
2017 Q4	$261K	Buy	+12,739	New	+$234K	0.15%	164

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ibex Investors's HALO Position: Q1 2018 in Review

Ibex Investors sold out of Halozyme (HALO) in Q1 2018, closing a stake of 12,739 shares — an estimated $261K sold.

Ibex Investors first reported a position in HALO in Q4 2017 and held it in 1 quarter. The position peaked at $261K in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2018.

Ibex Investors reported no remaining Halozyme position as of Q1 2018 after selling out during the quarter.
Ibex Investors sold 12,739 Halozyme shares in Q1 2018, an estimated $261K.
Ibex Investors first reported a position in Halozyme in Q4 2017 and held it in 1 quarter.
Ibex Investors's Halozyme position peaked at $261K in Q4 2017.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2018.

Based on Ibex Investors's 13F filing for Q1 2018, filed 15 May 2018.